IVMT at a Glance
Focus: Gastrointestinal cancer detection
Technology: Targeted peptide-based molecular imaging
Lead targets: EGFR and ErbB2 (HER2)
Imaging: Near-infrared fluorescence
Clinical application: Cholangioscopy and evaluation of indeterminate biliary strictures
Development stage: Phase II clinical development
Funding: NIH SBIR-supported
In Vivo Microsystems Technologies, LLC (IVMT) is a biotechnology company developing molecular imaging technologies designed to improve the detection and characterization of gastrointestinal cancers.
IVMT's platform combines targeted peptide ligands, molecular imaging, and advanced endoscopic technologies to provide clinicians with molecular information during image-guided procedures.
Many gastrointestinal diseases are difficult to diagnose using anatomical imaging and conventional biopsy alone. IVMT is developing targeted imaging agents designed to identify molecular features associated with disease, with the goal of providing actionable information during clinical procedures.
Our lead program focuses on indeterminate biliary strictures, a challenging clinical problem in which distinguishing benign from malignant disease can be difficult.
IVMT's lead imaging agent is a near-infrared fluorescent peptide heterodimer targeting EGFR and ErbB2 (HER2) for use during cholangioscopy.
IVMT's technology originated from academic research and has progressed through technology development, intellectual property licensing, SBIR-supported development, regulatory advancement, and clinical translation.
The company is currently advancing its lead molecular imaging program through a Phase II multi-center clinical study.
Our mission is to develop molecular imaging technologies that provide clinicians with more precise information at the point of care, supporting earlier cancer detection and more informed decisions during image-guided diagnosis and treatment.